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Addendum guidelines for the prevention of
peanut allergy in the United States: Report
of the National Institute of Allergy and
Infectious Diseases–sponsored expert panel
Alkis Togias1, Susan F. Cooper1*, Maria L. Acebal2, Amal Assa’ad3, James R. Baker Jr4, Lisa A. Beck5, Julie Block6,
Carol Byrd-Bredbenner7, Edmond S. Chan8, Lawrence F. Eichenfield9, David M. Fleischer10, George J. Fuchs III11,
Glenn T. Furuta12, Matthew J. Greenhawt10, Ruchi S. Gupta13, Michele Habich14, Stacie M. Jones15, Kari Keaton16,
Antonella Muraro17, Marshall Plaut1, Lanny J. Rosenwasser18, Daniel Rotrosen1, Hugh A. Sampson19,
Lynda C. Schneider21, Scott H. Sicherer20, Robert Sidbury22, Jonathan Spergel23, David R. Stukus24,
Carina Venter25 and Joshua A. Boyce26

Abstract
Background: Food allergy is an important public health problem because it affects children and adults, can be
severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of
Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the
first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other
emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods
beginning in infancy.
Objectives: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient
advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum
guidelines to specifically address the prevention of peanut allergy.
Results: The addendum provides 3 separate guidelines for infants at various risk levels for the development
of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include
the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral
food challenges), and the timing and approaches for introduction of peanut-containing foods in the health
care provider’s office or at home. The addendum guidelines provide the background, rationale, and strength
of evidence for each recommendation.
Conclusions: Guidelines have been developed for early introduction of peanut-containing foods into the
diets of infants at various risk levels for peanut allergy.
Keywords: Food, Peanut, Allergy, Prevention, Guidelines
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Introduction
Peanut allergy is a growing public health problem. In
1999, peanut allergy was estimated to affect 0.4% of children and 0.7% of adults in the United States [1], and by
2010, peanut allergy prevalence had increased to approximately 2% among children in a national survey [2],
with similar results reported in a regional cohort. [3]
Peanut allergy is the leading cause of death related to
food-induced anaphylaxis in the United States [4, 5], and
although overall mortality is low, the fear of lifethreatening anaphylactic reactions contributes significantly to the medical and psychosocial burden of
disease. In the majority of patients, peanut allergy begins
early in life and persists as a lifelong problem. Therefore,
cost-effective measures to prevent peanut allergy would
have a high effect in terms of improving public health,
reducing personal suffering, and decreasing health care
use and costs.
The “Guidelines for the diagnosis and management of
food allergy in the United States” [6] were published in
December 2010 by an Expert Panel and a Coordinating
Committee convened by the National Institute of Allergy
and Infectious Diseases (NIAID). These guidelines did
not offer strategies for the prevention of food allergy and
particularly peanut allergy because of a lack of definitive
studies at the time. The guidelines indicated that “insufficient evidence exists for delaying introduction of solid
foods, including potentially allergenic foods, beyond 4
to 6 months of age, even in infants at risk of developing allergic disease.” This statement differed from
previous clinical practice guidelines in the United
Kingdom [7] and United States [8], which recommended the exclusion of allergenic foods from the diets of infants at high risk for allergy and is consistent
with more recent recommendations regarding primary
allergy prevention [9–12].
In February 2015, the New England Journal of
Medicine published the results of the Learning Early
about Peanut Allergy (LEAP) trial [13]. This trial was
based on a prior observation [14] that the prevalence of
peanut allergy was 10-fold higher among Jewish children
in the United Kingdom compared with Israeli children
of similar ancestry. In Israel, peanut-containing foods
are usually introduced in the diet when infants are approximately 7 months of age and consumed in substantial amounts, whereas in the United Kingdom children
do not typically consume any peanut-containing foods
during their first year of life. The LEAP trial randomized
640 children between 4 and 11 months of age with severe eczema, egg allergy, or both to consume or avoid
peanut-containing foods until 60 months of age, at
which time a peanut oral food challenge (OFC) was conducted to determine the prevalence of peanut allergy.
LEAP trial participants were stratified at study entry into

Page 2 of 18

2 separate study cohorts on the basis of pre-existing
sensitization to peanut, as determined by means of skin
prick testing: one cohort consisted of infants with no
measureable skin test wheal to peanut (negative skin test
response) and the other consisted of those with measurable wheal responses (1–4 mm in diameter). Infants with
a 5 mm wheal diameter or greater were not randomized
because the majority of infants at this level of
sensitization were presumed to be allergic to peanut.
Among the 530 participants in the intention-to-treat
population with negative baseline skin test response to
peanut, the prevalence of peanut allergy at 60 months of
age was 13.7% in the peanut avoidance group and 1.9%
in the peanut consumption group (P < .001; an 86.1%
relative reduction in the prevalence of peanut allergy).
Among the 98 participants with a measurable peanut
skin test response at entry, the prevalence of peanut allergy was 35.3% in the avoidance group and 10.6% in the
consumption group (P = .004; a 70% relative reduction in
the prevalence of peanut allergy).
The LEAP trial was the first randomized trial to
study early allergen introduction as a preventive strategy. Because of the size of the observed effect and
the large number of study participants, its outcome
received wide publicity in both the medical community and the press. This raised the need to
operationalize the LEAP findings by developing clinical recommendations focusing on peanut allergy
prevention. To achieve this goal and its wide implementation, the NIAID invited the members of the
2010 Guidelines Coordinating Committee and other
stakeholder organizations to develop this addendum
on peanut allergy prevention to the 2010 “Guidelines
for the diagnosis and management of food allergy in
the United States.” Twenty-six stakeholder organizations participated in this 2015–2016 Coordinating
Committee. Of note, unrelated to this effort, a consensus statement on behalf of 9 international professional societies regarding the implications and
implementation of the LEAP trial findings was published as well [15].
Additional evidence on early introduction of allergenic
foods comes from the LEAP-On study [16], which demonstrated the durability of oral tolerance to peanut
achieved in the LEAP trial and the Enquiring About
Tolerance study [17], which assessed the potential benefits of early introduction of 6 allergenic foods in a non–
high-risk cohort.

Development of the 2017 addendum to the 2010
“Guidelines for the diagnosis and management of
food allergy”
The process to develop the 2017 addendum closely
followed that used in the 2010 guidelines [6].
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Coordinating Committee

The NIAID established a Coordinating Committee (CC),
the members of which are listed in Appendix A, to oversee the development of the addendum; review drafts of
the addendum for accuracy, practicality, clarity, and broad
utility of the recommendations in clinical practice; review
and approve the final addendum; and disseminate the addendum. The CC members represented 26 professional
organizations, advocacy groups, and federal agencies.

Page 3 of 18

develop recommendations for the diagnosis, treatment, and
management of patients. In assessing the body of evidence
of a group of relevant articles or of a single article, GRADE
considers study design and other factors, such as the precision, consistency, and directness of the data. By using this
approach, GRADE then provides a categorical assessment
of the contribution of individual publications and the overall
quality and strength of the body of evidence.
Each publication was assigned a grade according to
the following criteria [19, 20]:

Expert Panel

The CC convened an Expert Panel (EP) in June 2015
that was chaired by Joshua Boyce, MD. The 26 panel
members, listed in Appendix B, were specialists from a
variety of relevant clinical, scientific, and public health
areas. Panel members were nominated by the CC organizations, and the composition of the panel received
unanimous approval by the CC member organizations.
The charge to the EP was to use the literature review
prepared by the NIAID (see the next section) in conjunction with consensus expert opinion and EPidentified supplementary documents to (1) develop
evidence-based recommendations for the early introduction of dietary peanut to prevent peanut allergy; (2)
agree on principles for grading the evidence; (3) achieve
consensus while allowing ample opportunity for consideration of divergent opinions; (4) determine whether the
recommendations could extend beyond peanut to other
food allergens; and (5) keep patient and societal interests
at the forefront. The new recommendations are intended
to supplement and modify guidelines 37 to 40 in Section
5.3.4 of the 2010 guidelines: “Prevention of food allergy.”
Literature review

NIAID staff conducted a literature search of PubMed limited to the years 2010 (January) to 2016 (June). Using the
following specific search terms ([food allergy or milk allergy
or egg allergy or peanut allergy] OR [eczema or atopic
dermatitis] AND prevention), PubMed returned more than
1500 articles. NIAID staff reviewed 1506 abstracts and
assessed each for relevance to the topic of food allergy prevention with an emphasis on peanut allergy. Sixty-four publications (original research articles, editorials/letters, and
systematic reviews) were deemed relevant and placed into 2
tiers: tier 1 contained 18 items considered highly relevant
to the early introduction of peanut or other allergenic foods
(see Appendix C), and tier 2 contained 46 items on related
topics, such as food allergy or eczema prevention.
Assessing the quality of the body of evidence

For each of the 18 tier 1 references, the EP assessed quality
by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [18]. GRADE
provides a comprehensive and transparent methodology to

 High: Further research is very unlikely to have an

effect on the quality of the body of evidence, and
therefore the confidence in the recommendation is
high and unlikely to change.
 Moderate: Further research is likely to have an
effect on the quality of the body of evidence and
may change the recommendation.
 Low: Further research is very likely to have an
important effect on the body of evidence and is
likely to change the recommendation.
A GRADE designation of “low” for the quality of evidence
does not imply that an article is not factually correct or
lacks scientific merit. For example, a well-designed and executed single-site study of a treatment in a small cohort of
highly selected subjects may still yield an overall GRADE
rating of “low.” This is because such a study is characterized
as providing “sparse” data, and the patient population may
not be representative of the at-risk population. Each of these
factors reduces the level of evidence from “high,” which is
the initial designation for evidence from randomized controlled trials. It is worth emphasizing that these 2 limitations
are not of the study per se but of the body of evidence.
Preparation of the draft addendum

The draft version of the addendum, prepared by the NIAID,
contained 3 new guidelines and was reviewed, modified,
and endorsed by the EP members. The EP-approved document was forwarded to the CC members for review.
Public comment period, addendum revision, and final
approval

Concurrent with CC member review, the draft addendum
was posted to the NIAID Web site in March 2016 for a
period of 45 days to allow for public review and comment.
One hundred four comments were received. All comments
were reviewed by the EP and the CC, and some contributed to the final revision of the addendum. The final addendum was reviewed and approved by the EP and the CC.
Dissemination of the addendum guidelines

The final addendum is published herein and available
through the Internet.

Togias et al. World Allergy Organization Journal (2017) 10:1
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Defining the strength of each clinical guideline
The EP has used the verb “recommends” or “suggests”
for each clinical recommendation.
These words convey the strength of the recommendation, defined as follows:
 Recommend is used when the EP strongly

recommended for or against a particular course of
action.
 Suggest is used when the EP weakly recommended
for or against a particular course of action.

Addendum guidelines
Table 1 provides a summary of the 3 addendum guidelines to be used as a quick reference.
The EP came to consensus on the following 3 definitions used throughout the addendum guidelines.
 Severe eczema is defined as persistent or frequently

recurring eczema with typical morphology and
distribution assessed as severe by a health care
provider and requiring frequent need for
prescription-strength topical corticosteroids,
calcineurin inhibitors, or other anti-inflammatory
agents despite appropriate use of emollients.
 Egg allergy is defined as a history of an allergic
reaction to egg and a skin prick test (SPT) wheal
diameter of 3 mm or greater with egg white extract,
or a positive oral egg food challenge result.
 A specialist is defined as a health care provider with
the training and experience to (1) perform and
interpret SPTs and OFCs and (2) know and manage
their risks. Such persons must have appropriate
medications and equipment on site.
Addendum guideline 1

The EP recommends that infants with severe eczema, egg
allergy, or both have introduction of age-appropriate
peanut-containing food as early as 4 to 6 months of age to
reduce the risk of peanut allergy. Other solid foods should
be introduced before peanut-containing foods to show
that the infant is developmentally ready. The EP recommends that evaluation with peanut-specific IgE (peanut
sIgE) measurement, SPTs, or both be strongly considered

before introduction of peanut to determine if peanut
should be introduced and, if so, the preferred method of
introduction. To minimize a delay in peanut introduction
for children who may test negative, testing for peanut sIgE
may be the preferred initial approach in certain health care
settings, such as family medicine, pediatrics, or dermatology practices, in which skin prick testing is not routine.
Alternatively, referral for assessment by a specialist may
be an option if desired by the health care provider and
when available in a timely manner.
Figure 1 provides recommended approaches for evaluation of children with severe eczema, egg allergy, or both
before peanut introduction.
A peanut sIgE level of less than 0.35 kUA/L has strong
negative predictive value for the diagnosis of peanut allergy [21]. Therefore, peanut sIgE testing may help in
certain health care settings (eg, family medicine,
pediatric, or dermatology practices, where skin prick
testing is not routine) to reduce unnecessary referrals of
children with severe eczema, egg allergy, or both and to
minimize a delay in peanut introduction for children
who may have negative test results. However, the EP emphasizes that a peanut sIgE level of 0.35 kUA/L or
greater lacks adequate positive predictive value for the
diagnosis of peanut allergy, and an infant with a value of
0.35 kUA/L or greater should be referred to a specialist.
Thus, peanut sIgE testing can place an infant into one
of 2 categories (Fig. 1):
 sIgE Category A: If the peanut sIgE level is less than

0.35 kUA/L (ImmunoCAP), the EP recommends that
peanut should be introduced in the diet soon
thereafter, with a cumulative first dose of
approximately 2 g of peanut protein given in this
feeding. This can be given as a feeding at home
(Appendix D), considering the low likelihood of a
severe allergic reaction. If the caregiver or health
care provider has concerns, a supervised feeding can
be offered at the health care provider’s office
(Appendix E).
 sIgE Category B: If the peanut sIgE level is 0.35
kUA/L or greater (ImmunoCAP), the EP recommends
that the child be referred to a specialist for further
consultation and possible skin prick testing.

Table 1 Summary of addendum guidelines 1, 2, and 3
Addendum guideline

Infant criteria

Recommendations

Earliest age of peanut introduction

1

Severe eczema, egg allergy, or
both

Strongly consider evaluation by sIgE
measurement and/or SPT and, if
necessary, an OFC. Based on test results,
introduce peanut-containing foods.

4–6 months

2

Mild-to-moderate eczema

Introduce peanut-containing foods

Around 6 months

3

No eczema or any food allergy

Introduce peanut-containing foods

Age appropriate and in accordance with
family preferences and cultural practices

Togias et al. World Allergy Organization Journal (2017) 10:1
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Fig. 1 Recommended approaches for evaluation of children with severe eczema and/or egg allergy before peanut introduction. *To minimize a
delay in peanut introduction for children who may test negative, testing for peanut-specific Ige may be the preferred initial approach in certain
health care settings. Food allergen panel testing or the addition of sIgE testing for foods other than peanut is not recommended due to poor
positive predictive value

The EP does not recommend food allergen panel
testing or the addition of sIgE testing for foods other
than peanut because of their poor positive predictive
value, which could lead to misinterpretation, overdiagnosis of food allergy, and unnecessary dietary restrictions [6].
SPTs with peanut extract can place an infant in one of
3 categories (Fig. 1):
 SPT Category A: If an SPT to peanut extract

produces a wheal diameter of 2 mm or less above
saline control, the EP recommends that peanut be
introduced in the diet soon after testing, with a
cumulative first dose of approximately 2 g of peanut
protein given in this feeding. This can be given at
home (Appendix D), considering the low likelihood
of a severe allergic reaction. If the caregiver or
health care provider has concerns, a supervised
feeding can be offered at the health care provider’s
office (Appendix E).
 SPT Category B: If an SPT to peanut extract
produces a wheal diameter of 3 to 7 mm greater
than that elicited by the saline control, the EP
suggests that a supervised peanut feeding or a
graded OFC be undertaken at a specialist’s office or
a specialized facility (see Appendices E and G,
respectively). Infants in this category can be
sensitized without being allergic to peanut and
might benefit from early peanut consumption. If the

supervised peanut feeding or graded OFC yields no
reaction, the EP recommends that peanut should be
added to the child’s diet. If the supervised peanut
feeding or the graded OFC results in an allergic
reaction, the EP recommends that the child
should strictly avoid dietary peanut and the family
should be counseled regarding food allergy
management.
 SPT Category C: If an SPT produces a wheal
diameter 8 mm or greater than that elicited by
the saline control, the likelihood of peanut
allergy is high. Children in this category should
continue to be evaluated and managed by a
specialist. [21–23]
Box 1 Important considerations for skin prick testing
SPT reagents, testing devices, and methodology can differ
significantly among health care providers in the United States or
elsewhere [22]. The EP recommends that specialists adjust their
SPT categorization criteria according to their own training and
experience.
Health care providers conducting OFCs in infants with 3 mm or
greater SPT responses should be aware that the probability of a
positive challenge response increases with wheal size. These
data come from the HealthNuts Study in children 12 to
18 months of age; of note, the severity of these reactions was
relatively mild [21, 23].

Togias et al. World Allergy Organization Journal (2017) 10:1

How much dietary peanut protein to introduce

If the decision is made to introduce dietary peanut based
on the recommendations of addendum guideline 1, the
total amount of peanut protein to be regularly consumed
per week should be approximately 6 to 7 g over 3 or
more feedings (see Appendix F). In the LEAP trial, at
evaluations conducted at 12 and 30 months of age, 75%
of children in the peanut consumption group reported
eating at least this amount of peanut, based on analysis
of a 3-day food diary recorded just before the evaluation.
Rationale

Infants with severe eczema, egg allergy, or both are at high
risk for the development of peanut allergy. Significant evidence on this group is available from the infants who participated in the LEAP trial or were screened for the LEAP trial
but were not enrolled because of a large SPT response
(>4 mm). At 60 months of age, approximately 23% of peanut
avoiders and those infants not enrolled had food allergy [24].
Balance of benefits and harms

In the LEAP trial, among the 530 participants in the
intention-to-treat population with negative baseline SPT
responses to peanut, 13.7% of the avoidance group and
1.9% of the consumption group had peanut allergy at
60 months of age (P < .001; a 12.6% absolute risk reduction and an 86.1% relative risk reduction in the prevalence
of peanut allergy, resulting in a number needed to treat of
8.5 [number of infants needed to have early introduction
of peanut to prevent peanut allergy in one child]). Among
the 98 participants with positive peanut SPT responses at
entry, 35.3% of the avoidance group and 10.6% of the consumption group had peanut allergy at 60 months of age
(P = .004; a 24.7% absolute risk reduction and a 70% relative risk reduction in the prevalence of peanut allergy,
resulting in a number needed to treat of 4).
The LEAP-On study [24] demonstrated that the benefits
achieved in the LEAP trial persisted when LEAP trial peanut consumers subsequently avoided peanut for 1 year
from 60 to 72 months of age. This indicates that the oral
tolerance achieved in the LEAP trial was durable.
The LEAP trial did not include infants with SPT
wheals greater than 4 mm, and therefore no data are
available on the potential effectiveness of peanut consumption in preventing peanut allergy in this group.
However, EP members believe it is possible that some of
these infants may benefit from early introduction of peanut provided that they tolerate oral peanut.
As shown in Fig. 1, the EP recommends that infants
with severe eczema, egg allergy, or both, with peanut
sIgE levels of less than 0.35 kUA/L or with a peanut SPT
wheal of 2 mm or less have dietary peanut introduced as
early as 4 to 6 months of age without a need for further
evaluation. This recommendation is supported by expert
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opinion and analysis of the LEAP population findings. In
the LEAP trial, infants consuming peanut in this post
hoc defined category had a relative risk reduction of 79%
of having peanut allergy at 60 months of age compared
with infants who avoided peanut.
In the LEAP trial, at study entry, all infants randomly
assigned to the consuming group had a baseline peanut
OFC. Of the 272 infants with no wheal induced by peanut
SPT and who received a baseline oral peanut challenge,
only 1 had a reaction presenting as an erythematous urticarial rash that was graded as a “moderate” adverse event
and was treated successfully with chlorpheniramine.
Among the 29 infants with a wheal diameter of 1 to 2 mm
who received a baseline oral peanut challenge, 2 had reactions, which also presented with mild symptoms not requiring treatment with epinephrine. Therefore, for the
SPT Category A children, the risk of a severe reaction to
peanut at first introduction is low, and introduction of
peanut at home is an option. However, it is understandable that some caregivers of infants with severe eczema,
egg allergy, or both may be uncomfortable introducing
dietary peanut at home. In such cases the health care provider should offer the option of a supervised feeding of a
peanut-containing food in the office.
The rate of positive peanut OFC results at baseline for infants with a 3 to 4 mm wheal diameter (4/17 infants) was
higher than in infants with 0 to 2 mm wheal diameters (3/
301 infants), but the elicited symptoms were mild. Infants
with larger wheal diameters (>4 mm) were not included in
the LEAP trial, and therefore no safety data are available
from this group. However, based on the Australian HealthNuts study, which conducted peanut OFCs in a large number of older (12–18 months old) children from the general
Australian population, the rate of reactions to peanut is expected to be substantially higher with increasing SPT wheal
diameter [21, 23]. In the HealthNuts study [23] an SPT
wheal diameter of 8 mm or greater had a 95% positive predictive value for peanut allergy (positive oral peanut challenge result). Therefore, the EP recommends that for SPT
Category B infants (3 to 7 mm SPT wheal diameter), a supervised feeding or a graded peanut OFC should be conducted in a specialist’s office or a specialized facility
(Appendix G). SPT Category C infants are considered high
risk for established allergy to peanut and should not receive
peanut-containing foods in their diet, unless such foods are
recommended by a specialist after further evaluation.
Quality of evidence: Moderate

The designation of the quality of evidence as “moderate”
(as opposed to “high”) is based on the fact that this recommendation derives primarily from a single randomized,
open-label study: the LEAP trial. However, it should be
noted that the assessment of the LEAP trial’s primary outcome was based on a double-blind, placebo-controlled
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OFC. Furthermore, confidence in this recommendation is
bolstered by the large effect size demonstrated in the LEAP
trial and prior epidemiologic data that peanut allergy is
relatively infrequent in Israel, where early childhood consumption of peanut is common.
Contribution of expert opinion

Significant.
Additional comments

1. Breast-feeding recommendations: The EP recognizes
that early introduction of peanut may seem to depart
from recommendations for exclusive breast-feeding
through 6 months of age [25, 26]. However, it should
be noted that data from the nutrition analysis of the
LEAP cohort [27] indicate that introduction of peanut
did not affect the duration or frequency of breastfeeding and did not influence growth or nutrition.
2. Age of peanut introduction: For children with severe
eczema, egg allergy, or both, the EP recommends
that introduction of solid foods begins at 4 to
6 months of age, starting with solid food other than
peanut, so that the child can demonstrate the ability
to consume solid food without evidence of
nonspecific signs and symptoms that could be
confused with IgE-mediated food allergy. However, it
is important to note that infants in the LEAP trial
were enrolled between 4 and 11 months of age and
benefitted from peanut consumption regardless of
age at entry. Therefore, if the 4- to 6-month time
window is missed for any reason, including
developmental delay, infants may still benefit from
early peanut introduction. On the other hand, older
age at screening is associated with larger wheal
diameters induced by peanut SPT and hence a
higher likelihood of established peanut allergy [28].
A practical consideration for applying this guideline
at 4 to 6 months of age is that infants visit their
health care provider for well-child evaluations and
infant immunizations at this time. This provides a
fortuitous opportunity for eczema evaluation,
caregiver reporting of egg allergy, and, if needed,
referral to a specialist for peanut allergy evaluation
before dietary introduction of peanut.
3. Considerations for family members with established
peanut allergy: The EP recognizes that many infants
eligible for early peanut introduction under this
guideline will have older siblings or caregivers with
established peanut allergy. The EP recommends that
in this situation caregivers discuss with their health
care providers the overall benefit (reduced risk of
peanut allergy in the infant) versus risk (potential for
further sensitization and accidental exposure of the
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family member to peanut) of adding peanut to the
infant’s diet.
4. Children identified as allergic to peanut: For children
who have been identified as allergic to peanut, the
EP recommends strict peanut avoidance. This may
include those children in SPT Category B who fail
the supervised peanut feeding or the OFC, or those
children in SPT Category C who, on further
evaluation by a specialist, are confirmed as being
allergic to peanut. These children should be under
long-term management by a specialist.
Addendum guideline 2

The EP suggests that infants with mild-to-moderate eczema
should have introduction of age-appropriate peanutcontaining food around 6 months of age, in accordance with
family preferences and cultural practices, to reduce the risk
of peanut allergy. Other solid foods should be introduced
before peanut-containing foods to show that the infant is developmentally ready. The EP recommends that infants in
this category may have dietary peanut introduced at home
without an in-office evaluation. However, the EP recognizes
that some caregivers and health care providers may desire
an in-office supervised feeding, evaluation, or both.
Rationale

The LEAP trial did not target infants with mild or moderate
eczema. The EP considered the potential risk/benefit ratio of
early dietary peanut introduction in infants with mild-tomoderate eczema and concluded that the individual and societal benefits of introducing peanut in this population
would be significant. The EP has no reason to believe that
the mechanisms of protection of early dietary peanut differ
in infants with mild-to-moderate eczema from those that
lead to protection in infants at higher risk of peanut allergy.
Balance of benefits and harms

The LEAP trial included only infants with severe eczema
or egg allergy based on careful medical history. Therefore,
some infants who participated in the LEAP trial based on
the presence of egg allergy had atopic dermatitis severity
scores (SCORAD scores [29]) at screening that would
have placed them in the moderate or mild eczema category. The EP considered the outcomes of these children
and concluded that infants with mild-to-moderate eczema
would likely benefit from early peanut introduction.
Quality of evidence

Low.
The quality of evidence is low because this recommendation is based on extrapolation of data from a single study.
Contribution of expert opinion

Significant.
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Additional comment

Quality of evidence

Additional support for early introduction of peanut in
infants who do not have severe eczema comes from the
Enquiring About Tolerance study [17], which enrolled
infants from the general population at 3 months of age
and sequentially introduced 6 allergenic foods beginning
at the time of enrollment. These children were not
intentionally selected based on increased risk of food allergy or atopy. Although the intention-to-treat group did
not show benefit, most likely because of relatively poor
compliance with feeding recommendations, the children
in the per-protocol group who had peanut introduced
early in infancy showed a significant reduction in peanut
sensitization and peanut allergy at age 3 years. This
study also provides support for guideline 3 below.

Low.

Addendum guideline 3

Coordinating Committee member organizations and
representatives

The EP suggests that infants without eczema or any food allergy have age-appropriate peanut-containing foods freely
introduced in the diet together with other solid foods and in
accordance with family preferences and cultural practices.
Rationale

No evidence exists for restricting allergenic foods in infants without known risks for food allergy. The probability
for development of peanut allergy in such children is very
low. However, approximately 14% of all children with peanut allergy at age 12 to 18 months in the HealthNuts
Study lacked known risk factors for food allergy [16]. Consequently, because such children constitute a significant
majority of any birth cohort, they contribute substantially
to the overall societal burden of peanut allergy. The EP
finds no evidence to suggest that mechanisms of oral tolerance induction would differ in these infants from the
immunologic mechanisms that are protective in infants at
higher risk of peanut allergy. Thus, the early introduction
of dietary peanut in children without risk factors for peanut allergy is generally anticipated to be safe and to contribute modestly to an overall reduction in the prevalence
of peanut allergy. Furthermore, in countries such as Israel,
where peanut products are a popular component of the
diet and where they are introduced early in life, the prevalence of peanut allergy is low [14].
Balance of benefits and harms

The EP acknowledges that any analysis of benefit and
harm in this population relies primarily on expert opinion
and is subject to current differences in regional/societal
rates of peanut consumption and peanut sensitization. In
countries where peanut products are not widely consumed by adults, early dietary introduction of peanut
could lead to an increase in sensitization and allergic manifestations. Hence the EP cautions that this guideline be
implemented in the context of societal routines/norms.

Contribution of expert opinion

Significant.
Box 2 Clinical implications
These guidelines will help health care providers with early
introduction of peanut-containing foods in infants at various
risk levels for peanut allergy. Early introduction of peanut will
result in the prevention of peanut allergy in a large number
of infants.

Appendix A

Academy of Nutrition and Dietetics
http://www.eatright.org/
Alison Steiber, PhD, RD
Allergy & Asthma Network Mothers of Asthmatics
(AANMA)
http://www.allergyasthmanetwork.org/main/
Tonya A. Winders, MBA
American Academy of Allergy, Asthma & Immunology
(AAAAI)
https://www.aaaai.org/home.aspx
Hugh A. Sampson, MD
David Fleischer, MD
American Academy of Family Physicians (AAFP)
http://www.aafp.org/home.html
Jason Matuszak, MD
American Academy of Dermatology (AAD)
https://www.aad.org/
Lawrence F. Eichenfield, MD, FAAD
Jon Hanifin, MD
American Academy of Emergency Medicine (AAEM)
http://www.aaem.org/
Joseph P. Wood, MD, JD
American Academy of Pediatrics (AAP)
https://www.aap.org
Scott H. Sicherer, MD, FAAP
American Academy of Physician Assistants (AAPA)
https://www.aapa.org/
Gabriel Ortiz, MPAS, PA-C, DFAAPA
American College of Allergy, Asthma and Immunology
(ACAAI)
http://acaai.org/
Amal Assa’ad, MD
American College of Gastroenterology (ACG)
http://gi.org/
Steven J. Czinn, MD, FACG

Togias et al. World Allergy Organization Journal (2017) 10:1

American Partnership for Eosinophilic Disorders
(APFED)
http://apfed.org/
Wendy Book, MD
American Society for Nutrition (ASN)
http://www.nutrition.org/
George J. Fuchs III, MD
Asthma and Allergy Foundation of America
(AAFA)
http://www.aafa.org/
Meryl Bloomrosen, MBA, MBI
David R. Stukus, MD
Canadian Society of Allergy and Clinical Immunology
(CSACI)
http://www.csaci.ca/
Edmond Chan, MD, FRCPC
Eunice Kennedy Shriver National Institute of Child
Health & Human Development (NICHD)
https://www.nichd.nih.gov
Gilman Grave, MD
European Academy of Allergy and Clinical
Immunology (EAACI)
http://www.eaaci.org/
Antonella Muraro, MD, PhD
Food Allergy Research & Education (FARE)
https://www.foodallergy.org/
James R. Baker, MD
Mary Jane Marchisotto
National Eczema Association (NEA)
http://nationaleczema.org/
Julie Block
National Heart, Lung, and Blood Institute (NHLBI)
http://www.nhlbi.nih.gov/
Janet M. de Jesus, MS, RD
National Institute of Allergy and Infectious Diseases
(NIAID)
http://www.niaid.nih.gov/
Daniel Rotrosen, MD
Alkis Togias, MD
Marshall Plaut, MD
National Institute of Arthritis and Musculoskeletal
and Skin Diseases (NIAMS)
http://www.niams.nih.gov/
Ricardo Cibotti, PhD
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK)
www.niddk.nih.gov
Frank Hamilton, MD, MPH
Margaret A. McDowell, PhD, MPH, RD (retired)
Rachel Fisher, MS, MPH, RD
North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition (NASPGHAN)
http://www.naspghan.org/
Glenn Furuta, MD

Page 9 of 18

Society of Pediatric Nurses (SPN)
http://www.pedsnurses.org/
Michele Habich, DNP, APN/CNS, CPN
United States Department of Agriculture (USDA)
http://www.usda.gov/
Soheila J. Maleki, PhD
World Allergy Organization (WAO)
http://www.worldallergy.org/
Lanny J. Rosenwasser, MD

Appendix B
Expert Panel, June 2015

Chair
Joshua A. Boyce, MD
Professor of Medicine and Pediatrics
Harvard Medical School
Director, Inflammation and Allergic Disease Research
Section
Director, Jeff and Penny Vinik Center for Allergic
Disease Research
Specialty: Allergy/pediatric pulmonology
Panelists
Maria Acebal, JD
Board of Directors, Food Allergy Research & Education
Member of NIAID Advisory Council
Former CEO of Food Allergy and Anaphylaxis Network
Specialty: Advocacy
Amal Assa’ad, MD
Professor, University of Cincinnati Department of
Pediatrics
Director, FARE Center of Excellence in Food Allergy
Director of Clinical Services, Division of Allergy and
Immunology
Associate Director, Division of Allergy and Immunology
Cincinnati Children’s Hospital Medical Center
Specialty: Allergy/pediatrics
James R. Baker, Jr, MD
CEO and Chief Medical Officer
Food Allergy Research & Education, McLean VA
Founding Director, Mary H. Weiser Food Allergy
Center, University of Michigan
Professor of Internal Medicine, Division of Allergy and
Clinical Immunology
University of Michigan Health System
Specialty: Allergy/advocacy/education
Lisa A. Beck, MD
Professor, Department of Dermatology
University of Rochester Medical Center
School of Medicine and Dentistry
Specialty: Dermatology
Julie Block
President and CEO
National Eczema Association

Togias et al. World Allergy Organization Journal (2017) 10:1

Specialty: Advocacy/education
Carol Byrd-Bredbenner, PhD, RD, FAND
Professor of Nutrition/Extension Specialist
Rutgers University, School of Environmental and
Biological Sciences
Specialty: Nutrition/health communication/behavioral
science
Edmond S. Chan, MD, FRCPC
Clinical Associate Professor
Head, Division of Allergy and Immunology
Department of Pediatrics
BC Children’s Hospital
University of British Columbia
Specialty: Allergy/pediatrics
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Dermatology
Chief, Pediatric and Adolescent Dermatology
Rady Children’s Hospital, San Diego
University of California, San Diego School of
Medicine
Specialty: Dermatology/pediatrics
David M. Fleischer, MD
Associate Professor of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado, Aurora, CO
Specialty: Allergy/pediatrics
George J. Fuchs III, MD
Professor of Pediatrics
University of Kentucky College of Medicine
Chief, Gastroenterology, Nutrition & Hepatology
Kentucky Children’s Hospital
Specialty: Gastroenterology/pediatrics
Glenn T. Furuta, MD
Professor of Pediatrics
Director, Gastrointestinal Eosinophilic Diseases Program
University of Colorado School of Medicine
Children’s Hospital Colorado, Aurora, CO
Specialty: Gastroenterology/pediatrics
Matthew J. Greenhawt, MD, MBA, MSc
Assistant Professor of Pediatrics
Allergy Section
University of Colorado School of Medicine
Children’s Hospital Colorado, Aurora, CO
Specialty: Allergy/pediatrics
Ruchi Gupta, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Food Allergy Outcomes Research Program
Ann and Robert H. Lurie Children’s Hospital of Chicago
Northwestern Medicine, Northwestern University
Specialty: Pediatrics
Michele Habich, DNP, APN/CNS, CPN
Advanced Practice Nurse
Northwestern Medicine, Central DuPage Hospital
Specialty: Nursing/pediatrics/education

Page 10 of 18

Stacie M. Jones, MD
Professor of Pediatrics
University of Arkansas for Medical Sciences
Chief, Allergy and Immunology
Arkansas Children’s Hospital
Specialty: Allergy/pediatrics
Kari Keaton
Facilitator, Metro DC Food Allergy Support Group
Specialty: Advocacy/education
Antonella Muraro, MD, PhD
President of European Academy of Allergy and
Clinical Immunology (EAACI)
Professor of Allergy and Pediatric Allergy
Head of the Veneto Region Food Allergy Centre of
Excellence for Research and Treatment
University Hospital of Padua, Italy
Specialty: Allergy/pediatrics
Lanny J. Rosenwasser, MD
Immediate Past President, World Allergy Organization
Professor of Medicine
University of Missouri-Kansas City-School of Medicine
Specialty: Allergy/pediatrics
Hugh A. Sampson, MD
Professor of Pediatrics, Allergy and Immunology
Icahn School of Medicine at Mount Sinai
Director, Jaffe Food Allergy Institute
Specialty: Allergy/pediatrics
Lynda C. Schneider, MD
Professor of Pediatrics
Harvard Medical School
Director, Allergy Program
Boston Children’s Hospital
Specialty: Allergy/pediatrics
Scott H. Sicherer, MD
Professor Pediatrics, Allergy and Immunology
Icahn School of Medicine at Mount Sinai
Division Chief, Pediatric Allergy and Immunology
Specialty: Allergy/pediatrics
Robert Sidbury, MD, MPH
Professor
Department of Pediatrics
Chief, Division of Dermatology
Seattle Children’s Hospital
University of Washington School of Medicine
Specialty: Dermatology/pediatrics
Jonathan Spergel, MD, PhD
Stuart Starr Professor of Pediatrics
Chief, Allergy Section
Director, Center for Pediatric Eosinophilic Disorders
The Children’s Hospital of Philadelphia
Perelman School of Medicine, University of Pennsylvania
Specialty: Allergy/pediatrics
David R. Stukus, MD
Assistant Professor of Pediatrics

Togias et al. World Allergy Organization Journal (2017) 10:1

Page 11 of 18

Section of Allergy/Immunology
Nationwide Children’s Hospital
Columbus
Specialty: Allergy/pediatrics
Carina Venter, PhD, RD
Allergy Specialist, Dietitian
Cincinnati Children’s Hospital Medical Center
University of Cincinnati College of Medicine
Specialty: Allergy/dietitian/pediatrics

allergy phenotypes in a population cohort of infants: a latent class analysis. Clin Exp Allergy
2015;45:953–63.
Peters RL, Allen KJ, Dharmage SC, Koplin JJ, Dang T,
Tilbrook KP, et al. Natural history of peanut allergy
and predictors of resolution in the first 4 years
of life: a population-based assessment. J Allergy
Clin Immunol 2015;135:1257–66.e2.
Du Toit G, Roberts G, Sayre PH, Bahnson HT,
Radulovic S, Santos AF, et al. Randomized trial of
peanut consumption in infants at risk for peanut
allergy. N Engl J Med 2015;372:803–13.
Martin PE, Eckert JK, Koplin JJ, Lowe AJ, Gurrin
LC, Dharmage SC, et al. Which infants with
eczema are at risk of food allergy? Results from a
population-based cohort. Clin Exp Allergy
2015;45:255–64.
Grimshaw KE, Maskell J, Oliver EM, Morris RC, Foote
KD, Mills EN, et al. Introduction of complementary
foods and the relationship to food allergy. Pediatrics
2013;132:e1529–38.
Palmer DJ, Metcalfe J, Makrides M, Gold MS, Quinn P,
West CE, et al. Early regular egg exposure in
infants with eczema: a randomized controlled
trial. J Allergy Clin Immunol 2013;132:387–92.e1.
Du Toit G, Roberts G, Sayre PH, Plaut M,
Bahnson HT, Mitchell H, et al. Identifying infants at
high risk of peanut allergy: the Learning Early About
Peanut Allergy (LEAP) screening study. J Allergy
Clin Immunol 2013;131:135–43, e1-12.
Joseph CL, Ownby DR, Havstad SL, Woodcroft KJ,
Wegienka G, MacKechnie H, et al. Early
complementary feeding and risk of food sensitization
in a birth cohort. J Allergy Clin Immunol
2011;127:1203–10.e5.
Koplin JJ, Osborne NJ, Wake M, Martin PE, Gurrin
LC, Robinson MN, et al. Can early introduction of egg
prevent egg allergy in infants? A population-based
study. J Allergy Clin Immunol 2010;126:807–13.
Katz Y, Rajuan N, Goldberg MR, Eisenberg E,
Heyman E, Cohen A, et al. Early exposure to cow’s
milk protein is protective against IgE-mediated
cow’s milk protein allergy. J. Allergy Clin Immunol
2010;126:77–82.e1.

–

–

Appendix C
Tier 1 references

– Feeney M, Du Toit G, Roberts R, Sayre PH, Lawson K,
Bahnson HT, et al. Impact of peanut consumption in
the LEAP study: feasibility, growth and nutrition. J
Allergy Clin Immunol 2016;138:1108–18.
– Koplin JJ, Peters RL, Dharmage SC, Gurrin L,
Tang MLK, Ponsonby AL, et al. Understanding
the feasibility and implications of implementing
early peanut introduction for prevention of
peanut allergy. J Allergy Clin Immunol
2016;138:1131–41.e2.
– Perkin MR, Logan K, Tseng A, Raji B, Ayis S,
Peacock J, et al. Randomized trial of introduction of
allergenic foods in breast-fed infants. N Engl J Med
2016;374:1733–43.
– Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson
K, Bahnson HT, et al. Effect of avoidance on peanut
allergy after early peanut consumption. N Engl J
Med 2016;374:1435–43.
– Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L,
García-Romero MT. Synbiotics for prevention and
treatment of atopic dermatitis: a meta-analysis of
randomized clinical
trials.
JAMA
Pediatr
2016;170:236–42.
– O’Connor C, Kelleher M, O’B Hourihane J. Calculating
the effect of populationlevel implementation of the
Learning Early About Peanut Allergy (LEAP) protocol
to prevent peanut allergy. J Allergy Clin Immunol
2016;137:1263–4.e2.
– Grimshaw KE, Bryant T, Oliver EM, Martin J,
Maskell J, Kemp T, et al. Incidence and risk
factors for food hypersensitivity in UK infants:
results from a birth cohort study. Clin Transl
Allergy 2016;6:1.
– Rabinovitch N, Shah D, Lanser BJ. Look before
you LEAP: risk of anaphylaxis in high-risk infants
with early introduction of peanut. J Allergy Clin
Immunol 2015;136:822.
– Peters RL, Allen KJ, Dharmage SC, Lodge CJ,
Koplin JJ, Ponsonby AL, et al. Differential
factors associated with challenge-proven food

–

–

–

–

–

–

–

Appendix D
Instructions for home feeding of peanut protein for
infants at low risk of an allergic reaction to peanut

These instructions for home feeding of peanut protein
are provided by your doctor. You should discuss any
questions that you have with your doctor before starting.
These instructions are meant for feeding infants who
have severe eczema or egg allergy and were allergy
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tested (blood test, skin test, or both) with results that
your doctor considers safe for you to introduce peanut
protein at home (low risk of allergy).
General instructions

1. Feed your infant only when he or she is healthy; do
not do the feeding if he or she has a cold, vomiting,
diarrhea, or other illness.
2. Give the first peanut feeding at home and not at a
day care facility or restaurant.
3. Make sure at least 1 adult will be able to focus all
of his or her attention on the infant, without
distractions from other children or household
activities.
4. Make sure that you will be able to spend at least
2 h with your infant after the feeding to watch for
any signs of an allergic reaction.
Feeding your infant

1. Prepare a full portion of one of the peanutcontaining foods from the recipe options below.
2. Offer your infant a small part of the peanut serving
on the tip of a spoon.
3. Wait 10 min.
4. If there is no allergic reaction after this small
taste, then slowly give the remainder of the
peanut-containing food at the infant’s usual eating
speed.
What are symptoms of an allergic reaction? What should I
look for?
 Mild symptoms can include:

○ a new rash

or
○ a few hives around the mouth or face
 More severe symptoms can include any of the

following alone or in combination:
○ lip swelling
○ vomiting
○ widespread hives (welts) over the body
○ face or tongue swelling
○ any difficulty breathing
○ wheeze
○ repetitive coughing
○ change in skin color (pale, blue)
○ sudden tiredness/lethargy/seeming limp
If you have any concerns about your infant’s response to peanut, seek immediate medical attention/
call 911.
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Four recipe options, each containing approximately 2 g
of peanut protein

Note: Teaspoons and tablespoons are US measures (5
and 15 mL for a level teaspoon or tablespoon,
respectively).
Option 1: Bamba (Osem, Israel), 21 pieces (approximately
2 g of peanut protein)
Note: Bamba is named because it was the product
used in the LEAP trial and therefore has proven
efficacy and safety. Other peanut puff products
with similar peanut protein content can be
substituted.
a. For infants less than 7 months of age, soften the
Bamba with 4 to 6 teaspoons of water.
b. For older infants who can manage dissolvable
textures, unmodified Bamba can be fed. If
dissolvable textures are not yet part of the
infant’s diet, softened Bamba should be
provided.
Option 2: Thinned smooth peanut butter, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter and slowly
add 2 to 3 teaspoons of hot water.
b. Stir until peanut butter is dissolved, thinned, and
well blended.
c. Let cool.
d. Increase water amount if necessary (or add previously
tolerated infant cereal) to achieve consistency
comfortable for the infant.
Option 3: Smooth peanut butter puree, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter.
b. Add 2 to 3 tablespoons of pureed tolerated fruit or
vegetables to peanut butter. You can increase or
reduce volume of puree to achieve desired
consistency.
Option 4: Peanut flour and peanut butter powder, 2
teaspoons (4 g of peanut flour or 4 g of peanut
butter powder; approximately 2 g of peanut
protein)
Note: Peanut flour and peanut butter powder are
2 distinct products that can be interchanged because they have a very similar peanut protein
content.
a. Measure 2 teaspoons of peanut flour or peanut
butter powder.
b. Add approximately 2 tablespoons (6–7
teaspoons) of pureed tolerated fruit or
vegetables to flour or powder. You can increase
or reduce volume of puree to achieve desired
consistency.

Togias et al. World Allergy Organization Journal (2017) 10:1

Appendix E
For health care providers: In-office supervised feeding
protocol using 2 g of peanut protein
General instructions

1. These recommendations are reserved for an infant
defined in guideline 1 as one with severe eczema, egg
allergy, or both and with negative or minimally
reactive (1 to 2 mm) SPT responses and/or peanut
sIgE levels of less than 0.35 kUA/L. They also may
apply to the infant with a 3 to 7 mm SPT response if
the specialist health care provider decides to conduct
a supervised feeding in the office (as opposed to a
graded OFC in a specialized facility [see Fig. 1]).
These recommendations can also be followed for infants with mild-to-moderate eczema, as defined in
guideline 2, when caregivers and health care providers
may desire an in-office supervised feeding.
2. Proceed only if the infant shows no evidence of any
concomitant illness, such as an upper respiratory
tract infection.
a. Start with a small portion of the initial peanut
serving, such as the tip of a teaspoon of peanut
butter puree/softened Bamba.
b. Wait 10 min; if there is no sign of reaction after
this small portion is given, continue gradually
feeding the remaining serving of peanutcontaining food (see options below) at the infant’s typical feeding pace.
c. Observe the infant for 30 min after 2 g of peanut
protein ingestion for signs/symptoms of an
allergic reaction.
Four recipe options, each containing approximately 2 g of
peanut protein

Note: Teaspoons and tablespoons are US measures (5 and
15 mL for a level teaspoon or tablespoon, respectively).
Option 1: Bamba (Osem, Israel), 21 pieces (approximately
2 g of peanut protein)
Note: Bamba is named because it was the product used
in the LEAP trial and therefore has known peanut protein content and proven efficacy and safety. Other peanut puffs products with similar peanut protein content
can be substituted for Bamba.
a. For infants less than 7 months of age, soften the
Bamba with 4 to 6 teaspoons of water.
b. For older infants who can manage dissolvable
textures, unmodified Bamba can be fed. If
dissolvable textures are not yet part of the infant’s
diet, softened Bamba should be provided.
Option 2: Thinned smooth peanut butter, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
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a. Measure 2 teaspoons of peanut butter and slowly
add 2 to 3 teaspoons hot water.
b. Stir until peanut butter is dissolved and thinned
and well blended.
c. Let cool.
d. Increase water amount if necessary (or add
previously tolerated infant cereal) to achieve
consistency comfortable for the infant.
Option 3: Smooth peanut butter puree, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter.
b. Add 2 to 3 tablespoons of previously tolerated
pureed fruit or vegetables to peanut butter. You can
increase or reduce volume of puree to achieve
desired consistency.
Option 4: Peanut flour and peanut butter powder, 2
teaspoons (4 g of peanut flour or 4 g of peanut butter
powder; approximately 2 g of peanut protein)
Note: Peanut flour and peanut butter powder are 2 distinct products that can be interchanged because they
have, on average, a similar peanut protein content.
a. Measure 2 teaspoons of peanut flour or peanut
butter powder.
b. Add approximately 2 tablespoons (6–7 teaspoons)
of pureed tolerated fruit or vegetables to flour or
powder. You can increase or reduce the volume of
puree to achieve desired consistency.

Appendix F
Peanut protein in peanut-containing foods

If the decision is made to introduce dietary peanut to
the infant’s diet, the total amount of peanut protein to
be regularly consumed per week should be approximately 6 to 7 g over 3 or more feedings. In the LEAP
trial, at evaluations conducted at 12 and 24 months of
age, 75% of children in the peanut consumption group
reported eating at least this amount of peanut.
Be aware of choking risks
 Whole nuts should not be given to children less

than 5 years of age.
 Peanut butter directly from a spoon or in lumps/

dollops should not be given to children less than
4 years of age.
If, after a week or more eating peanut, your infant or
child displays mild allergic symptoms within 2 h of eating peanut, you should contact your health care
provider.
Typical peanut-containing foods, their peanut protein
content, and feeding tips for infants are provided in
Table 2, and their nutritional content is found in Table 3.
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Table 2 Typical peanut-containing foods, their peanut protein content, and feeding tips for infants
Bamba

Peanut butter

Peanuts

Peanut flour or peanut
butter powder

Amount containing
approximately
2 g of peanut protein

17 g or 2 =3 of a 28-g (1-oz)
bag or 21 sticks

9–10 g or 2 teaspoons

8 g or ~ 10 whole peanuts
(21 =2 teaspoons of
grounded peanuts)

4 g or 2 teaspoons

Typical serving size

1 bag (28 g)

Spread on a slice of bread
or toast (16 g)

21 =2 teaspoons of ground
peanuts (8 g)

No typical serving size

Peanut protein per
typical serving

3.2 g

3.4 g

2.1 g

No typical serving size

Feeding tips

For a smooth texture, mix with
warm water (then let cool) or
breast milk or infant formula
and mash well. Pureed or
mashed fruit or vegetables
can be added. Older children
can be offered sticks of Bamba.

For a smooth texture, mix with
warm water (then let cool) or
breast milk or infant formula.
For older children, mix with
pureed or mashed fruit or
vegetables or any suitable
family foods, such as yogurt
or mashed potatoes.

Use blender to create a
powder or paste. 2–21 =2
teaspoons of ground
peanuts can be added to
a portion of yogurt or
pureed fruit or savory meal.

Mix with yogurt or
apple sauce.

Notes: Bamba (Osem, Israel) is named because it was the product used in the LEAP trial and therefore has known peanut protein content and proven efficacy and
safety. Other peanut puff products with similar peanut protein content can be substituted for Bamba
Teaspoons and tablespoons are US measures (5 and 15 mL for a level teaspoon or tablespoon, respectively)

Table 3 Nutritional content of peanut-containing foods
Per approximately 2 g of peanut protein

Bambaa (17 g)

Peanut butter (10 g)

Peanuts (8 g)

Peanut butter powder (4 g)

Peanut flour (4 g)

kcal

93

59

45

15

13

Sugar (g)

0.4

0.65

0.38

0.4

0.33

Salt (mg)

68

48

1

31

7

Fat (g)

6.1

4.95

3.94

0.49

0.02

a

The nutritional content of peanut puff products (other than Bamba) can be obtained from their manufacturers

Appendix G
Graded OFC protocol

From “Conducting an oral food challenge to peanut in
an infant: a work group report.” [30]
General instructions

1. A graded OFC should be performed only by a
specialist with the training and experience to (1)
perform and interpret skin prick testing and OFCs
and (2) know and manage their risks. Such persons
must have appropriate medications and equipment
on site.
2. Four peanut preparations are provided:
a. Option 1: Smooth peanut butter mixed with
either a previously tolerated pureed fruit or
vegetable.
b. Option 2: Smooth peanut butter dissolved
carefully with hot water and cooled.
c. Option 3: Peanut flour mixed with either a
previously tolerated pureed fruit or vegetable.
Peanut butter powder can be used instead of the
peanut flour.

d. Option 4: Bamba peanut snack dissolved in hot
water and cooled or even as a solid (ie, as a
stick).
Note: Bamba (Osem, Israel) is named because it was
the product used in the LEAP trial and therefore has
known peanut protein content and proven efficacy and
safety. Other peanut puff products with similar peanut
protein content can be substituted for Bamba.
3. The peanut protein content of the graded OFC
protocol is identical for all peanut preparations
provided below, except that the volume of food
ingested per dose is different. The protocol consists of
5 incremental doses, given 15 to 20 min apart, with a
cumulative peanut protein total of approximately 4 g
per the 3.9 g total in the LEAP trial.
4. Refer to Table 4 and direct parents to discontinue
specific medications for the prescribed amount of
time before the graded OFC. Note that certain
medications are allowed.
Be prepared in case of a severe reaction (see Table 5)

Note: Teaspoons and tablespoons are US measures (5
and 15 mL for a level teaspoon or tablespoon, respectively).
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Option 1: Measures for smooth peanut butter puree
Dose

Peanut butter volumea

1

1

2

Equivalent weight of peanut butter
(g [peanut protein content in grams])b

Pureed fruit or vegetable volume

Total volume

=8 teaspoon

0.67 (0.15)

1

=2 teaspoon

5

1

=4 teaspoon

1.33 (0.29)

3

=4 teaspoon

1 teaspoons

3

1

=2 teaspoon

2.67 (0.59)

1 teaspoons

11 =2 teaspoons

4

1 teaspoon

5.33 (1.17)

2 teaspoons

3 teaspoonsc

5

11 =2 teaspoons

8 (1.6)

4 teaspoons

51 =2 teaspoons

=8 teaspoon

Total protein: 3.96 g
a

Amounts (volume) of peanut butter measured as teaspoons are approximate measures to keep the dosing as practical as possible
Peanut protein content is calculated on the average amount of protein for a range of butters using “Report: 16167, USDA Commodity, Peanut Butter, smooth,”
from the USDA Nutrition Database (http://ndb.nal.usda.gov/ndb/foods)
c
Three teaspoons = 1 tablespoon
b

Option 2: Measures for smooth thinned peanut butter

Dose

Peanut butter volumea

1

1

2

Equivalent weight peanut butter
(g [peanut protein content in grams])b

Volume of hot water

Total volume

=8 teaspoon

0.67 (0.15)

1

=8 teaspoon

1

=4 teaspoon

1

=4 teaspoon

1.33 (0.29)

1

=4 teaspoon

1

=2 teaspoon

=2 teaspoon

=2 teaspoon

3

1

2.67 (0.59)

1

4

1 teaspoon

5.33 (1.17)

1 teaspoon

2 teaspoons

5

11 =2 teaspoons

8 (1.76)

11 =2 teaspoons

3 teaspoonsc

1 teaspoon

Total protein: 3.96 g
a

Amounts (volume) of peanut butter measured as teaspoons are approximate measures to keep the dosing as practical as possible
Peanut protein content is calculated on the average amount of protein for a range of butters using “Report: 16167, USDA Commodity, Peanut Butter, smooth,”
from the USDA Nutrition Database (http://ndb.nal.usda.gov/ndb/foods)
c
Three teaspoons = 1 tablespoon
b

Option 3: Measures for peanut flour or peanut butter powder

Equivalent weight peanut flour or peanut butter
powderb (g [peanut protein content in grams])

Pureed fruit or vegetable
volume

=8 teaspoon

0.25 (0.13)

1

1

=4 teaspoon

0.5 (0.25)

1 teaspoon

11 =4 teaspoons

3

1

=2 teaspoon

1.0 (0.5)

2 teaspoons

21 =2 teaspoons

4

1 teaspoon

2.0 (1.0)

3 teaspoonsc

4 teaspoons

4.0 (2.0)

d

8 teaspoons

Dose

Peanut flour or peanut butter
powder volumea

1

1

2

5

2 teaspoons

=2 teaspoon

6 teaspoons

Total volume
3

=4 teaspoon

Total protein: 3.88 g
a

Amounts (volume) of peanut flour or peanut butter powder measured as teaspoons are approximate measures to keep the dosing as practical as possible
Information regarding peanut powder and flour reflects averages obtained from the producers. Most brands of peanut flour/peanut butter powder are
approximately 50% peanut protein by weight. However, weight can vary based on the fat content and also the brand chosen. Therefore a weight measurement
can be more accurate than household measurements
c
Three teaspoons = 1 tablespoon
d
Six teaspoons = 2 tablespoons
b
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Table 4 Medication discontinuation considerations before OFC

Protocol instructions for options 1, 2, and 3

1. Measure peanut butter, peanut flour, or peanut
butter powder for dose 1.
2. Prepare the first dose:
a. If using option 1, add previously tolerated
pureed fruit or vegetable to measured dose 1
peanut butter and stir until well blended. You
can increase or reduce volume of puree to
achieve desired consistency. Note: Increasing the
volume may increase the difficulty of getting
through the entire protocol with a young baby.
b. If using option 2, slowly add hot water to
measured dose 1 peanut butter and stir until
peanut butter is dissolved, thinned, and well
blended. Let the mixture cool. You can increase
water volume (or add previously tolerated infant
cereal) to achieve desired consistency.
c. If using option 3, add previously tolerated
pureed fruit or vegetable to measured dose 1
peanut flour or peanut butter powder and stir
until well blended. You can increase or reduce
volume of puree to achieve desired consistency.
Note: Increasing the volume may increase the
difficulty of getting through entire protocol with
a young baby.
3. Label dose 1.
4. Repeat steps 1 to 3 for the remaining doses 2
through 5, labeling each dose appropriately and
before proceeding to the preparation of the next
dose.
5. Feed dose 1 to infant and observe for symptoms of
reactivity for 15 to 20 min.
6. If no symptoms appear, repeat with dose 2 and
observe for 15 to 20 min.
7. Continue in this manner with doses 3, 4, and 5.
Option 4: Bamba peanut snack (Osem, Israel)

Dose Bamba,
Equivalent weight Volume of hot water Approximate
no. of sticks (peanut protein
(approximate, will
final volume
content [g])a
need to be adjusted
for each child)
=2 teaspoon

3

1 stick

0.81 (0.1)

1

2

3 sticks

2.43 (0.3)

1 teaspoon

11 =2 teaspoons

3

5 sticks

4.05 (0.5)

1 =2 teaspoons

21 =4 teaspoons

4

10 sticks

8.1 (1.0)

3 teaspoons

4 teaspoons

6 teaspoons

7 =2 teaspoons

5

21 sticks

17.01 (2.0)

Medications to be discontinued

Last dose before OFC

Cetirizine

5 days

Cyproheptadine

10 days

Diphenhydramine

3 days

Fexofenadine

3 days

Loratadine

7 days

Short-acting bronchodilator (eg, albuterol)

8h

Medications that can be continued
Antihistamine eye drops
Inhaled/intranasal corticosteroids
Topical (cutaneous) steroids
Topical (cutaneous) pimecrolimus, tacrolimus

Protocol instructions for option 4

1. Count Bamba sticks for dose 1.
2. Prepare the first dose by slowly adding hot water to
measured Bamba and stirring until Bamba is
dissolved, thinned, well blended, and cooled. You
can increase water volume to achieve desired
consistency. Note: Increasing the volume may
increase the difficulty of getting through the entire
protocol with a young baby.
Table 5 Emergency medications for a severe reaction during an
office-based infant OFC
Medication

Dose

First-line
treatment

Epinephrine
(1:1000 concentration)

0.01 mg/kg IM in the mid-outer
thigh in health care settings
or 0.15 mg of autoinjector
IM in the mid-outer thigh in
community settings Epinephrine
doses may need to be repeated
every 5–15 min

Adjunctive
treatment

Albuterol nebulization

0.15 mg/kg every 20 min × 3
doses (minimum of 2.5 mg per
dose) over 5–15 min

Albuterol MDI
inhalation

2 puffs, 90 μg per puff, with
face mask

Oxygen

8–10 L/min through a face
mask

Diphenhydramine

1.25 mg/kg administered
orally

Cetirizine

2.5 mg administered
orally

Normal saline (0.9%
isotonic solution) or
lactated ringers

20 ml/kg per dose administered
over 5 min intravenously

Steroids

Prednisolone 1 mg/kg
administered orally or SoluMedrol 1 mg/kg administered
intravenously

=4 teaspoons

1

1
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1

Total protein:
3.9 g
Note: Other peanut puffs products with equivalent peanut protein content can
be substituted for Bamba
a
The amount of Bamba sticks is an approximate measure looking at a range of
Bamba products. Bamba snacks from different parts of the world have a varied
peanut protein content [30]. The peanut protein content of Bamba was
calculated according to the publication by Du Toit et al. [13]

IM Intramuscular, MDI metered-dose inhaler
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3. Label dose 1.
4. Repeat steps 1 to 3 for the remaining doses 2
through 5, labeling each dose appropriately
and before proceeding to the preparation of
the next dose.
5. Feed dose 1 to the infant and observe for symptoms
of reactivity for 15 to 20 min.
6. If no symptoms appear, repeat with dose 2 and
observe for 15 to 20 min.
7. Continue in this manner with doses 3, 4, and 5.
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